Health News Archive - February 04, 2010
PARIS and LAUSANNE, Switzerland, February 4 /PRNewswire/ -- Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- VaxGen, Inc.
ALISO VIEJO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Clarient, Inc.
SAN ANTONIO, Feb.
SAN ANTONIO, Feb. 4 /PRNewswire-USNewswire/ -- Doctors from the Mayo Clinic in Jacksonville, Florida showcased positive results of peripheral nerve stimulation (PNS) in a patient suffering from post-herpetic neuralgia (PHN), or pain after a herpes breakout.
BIRMINGHAM, Ala., Feb. 4 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc.
CARLSBAD, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Genoptix, Inc.
WALTHAM, Mass., Feb. 4 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that it will make a corporate presentation at the 2010 BIO CEO & Investor Conference.
MOUNTAIN VIEW, Calif., Feb. 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Dr.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.